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Author Reply: Decision-Making Management
of Women with a High Risk of Developing Breast
and Ovarian Cancer
To the Editor:
With great attention we read the letter from Briasoulis
et al. and appreciate the opportunity to reply to it.
We agree with Briasoulis et al. that decision-making
management of women with a highly increased risk of
developing breast and ovarian cancer is very complex.
However, compared with other options to reduce the risk of
developing breast cancer (BC), including prophylactic
bilateral salpingo-oophorectomy (PBSO) and surveillance,
prophylactic mastectomy (PM) remains the most effective
preventive intervention at this moment. Both our present
study as well as the prospective study by Meijers-Heijboer
et al.1 showed no breast cancer occurrence after PM in
unaffected high-risk women. This indicates a risk reduction
of developing breast cancer of at least 90%, while other
preventive options result in a risk reduction of approxi-
mately 50% at the most. Although these data are not
available yet, it is expected that PM ultimately will result in a
significant mortality reduction in this group after longer
follow-up, which is the ultimate goal. Regarding the group
of women with a history of breast cancer undergoing PM,
neither contralateral breast cancer nor local recurrence oc-
curred after bilateral or contralateral PM. These data are
reassuring in view of the fact that BRCA1/2 mutation car-
riers are known to have a significantly higher risk of con-
tralateral breast cancer and potentially a higher risk of
ipsilateral recurrence thought to be a new primary breast
cancer.2,3 Furthermore, in mutation carriers/high-risk wo-
men with remaining breast tissue regular surveillance,
including imaging examinations, is still indicated, which is
not the case after PM. Although there are no data available
from cost-effectiveness analyses, it is plausible that PM
might bemore cost-effective than other preventive options in
unaffected mutation carriers. Also, without underestimating
the impact on quality of life and especially on the quality of
the sexual relationship, it has been shown that distress levels
in women opting for PM had significantly decreased after
surgery, that most women are satisfied with their decision,
and that they would choose the procedure again.4,5 It is
possible that cultural differences may play a role in the
decision-making process and at least partly explain the dif-
ference with respect to attitudes and choices hereby.
The comment of the authors that given the lack of dif-
ference in overall survival between BRCA1/2-associated
and sporadic breast cancer, as reported in a recent study,
the value of genetic testing as well as any prophylactic
interventions is questionable is very surprising. First, a
nonsignificantly different survival in BRCA1 and BRCA2
compared with sporadic breast cancer has also previously
been reported by our and other groups and therefore is not
a new observation. Second, and most important, most of
the available survival data have been obtained from retro-
spective studies. The concrete goals of genetic testing and
appropriate measures for identified mutation carriers are to
identify these women and include them in surveillance
programs enabling early detection and/or prevention of the
occurrence of breast/ovarian cancer. It is our opinion that
in this way lives can be saved, although data from pro-
spective studies have to be awaited.
To overcome the challenges of the complex decision-
making management of BRCA mutation carriers and of
dealing with women who have a strong family history but
tested negative for a BRCA mutation, the Ioannina
University developed a comprehensive, decision-making
algorithm.6 Comparing this algorithm with our guidelines,
we noticed some striking differences. First, in the Nether-
lands proven noncarriers from a family with a BRCA
mutation are not considered anymore to have a signifi-
cantly increased risk of developing breast and/or ovarian
cancer compared with the general population. Therefore,
according to our institutional and national guidelines,
increased surveillance, or any other preventive options, are
not recommended for these women.7 Second, at our insti-
tute systematic testing for CHEK2 mutations has not been
incorporated yet in the standard diagnostic genetic testing,
as we previously reported incomplete cosegregation of the
CHEK2 1100delC genotype with the breast cancer pheno-
type.8 This strategy is also used in other institutions in the
Netherlands. Certainly, this may be reconsidered if further
data become available,9 although incomplete cosegregation
remains a problem to be solved.
The observations that routine practices at the moment
still differ between the Netherlands and Greece is only
emphasizing the importance of further studies into the
subject to be carried out in order to obtain more evidence-
based data with respect to both BRCA- and non-BRCA-
associated breast cancer. This warrants joint efforts of
national and international working groups.
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